29 Sept 2026, 11:05
Director Interests—
AGNARGENICA THERAPEUTICS LIMITED
Announcement history available from 1 August 2025
Fromto
23 Sept 2026, 08:16
Meetings & Governance—
15 Sept 2026, 08:12
Company Update—
26 Aug 2026, 16:35
Company Administration—
26 Aug 2026, 16:29
Financial ResultsMS
13 Aug 2026, 17:32
Securities Administration—
27 July 2026, 09:13
Presentations—
24 July 2026, 09:18
Quarterly ReportsMS
16 July 2026, 08:27
Company UpdateMS
11 June 2026, 08:33
Presentations—
11 June 2026, 08:33
Presentations—
11 June 2026, 08:33
Company UpdateMS
10 June 2026, 08:19
Company UpdateMS
9 June 2026, 14:13
Securities Administration—
26 May 2026, 09:52
Securities Administration—
21 May 2026, 09:01
Company UpdateMS
14 May 2026, 09:15
Company UpdateMS
29 Apr 2026, 08:20
Quarterly ReportsMS
16 Apr 2026, 09:15
Presentations—
26 Mar 2026, 08:13
Company AdministrationMS
17 Mar 2026, 08:19
Periodic ReportsMS
11 Feb 2026, 08:17
Financial ResultsMS
5 Feb 2026, 08:23
Presentations—
2 Feb 2026, 09:01
Company UpdateMS
28 Jan 2026, 08:15
Quarterly ReportsMS
2 Jan 2026, 16:53
Director Interests—
29 Dec 2025, 08:27
Company Administration—
11 Dec 2025, 09:11
Company UpdateMS
4 Dec 2025, 08:17
Company UpdateMS
25 Nov 2025, 09:16
Company UpdateMS
12 Nov 2025, 19:05
Director Interests—
12 Nov 2025, 19:03
Meetings & Governance—
12 Nov 2025, 16:53
Presentations—
12 Nov 2025, 16:49
Company Administration—
31 Oct 2025, 09:16
Quarterly ReportsMS
21 Oct 2025, 09:04
Presentations—
20 Oct 2025, 13:16
Securities Administration—
15 Oct 2025, 08:28
Company UpdateMS
13 Oct 2025, 14:09
Meetings & Governance—
24 Sept 2025, 10:49
Presentations—
17 Sept 2025, 08:57
Meetings & Governance—
4 Sept 2025, 08:17
Substantial Holders—
3 Sept 2025, 09:37
Company Administration—
3 Sept 2025, 09:35
Presentations—
3 Sept 2025, 09:34
Company UpdateMS
1 Sept 2025, 09:01
Trading Halt / SuspensionMS
28 Aug 2025, 17:06
Company Administration—
28 Aug 2025, 17:05
Financial ResultsMS
14 Aug 2025, 09:08
Company UpdateMS
8 Aug 2025, 09:11
Presentations—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 29 Sept 2026, 11:05 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 23 Sept 2026, 08:16 | AGM Date & Closing Date for Director Nominations | Meetings & Governance | — | 08006 | |
| 15 Sept 2026, 08:12 | Concussion Data Selected for Neurotrauma Congress | Company Update | — | 11001 | |
| 26 Aug 2026, 16:35 | Appendix 4G & Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 26 Aug 2026, 16:29 | Appendix 4E & Annual Report to 30 June 2026 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 13 Aug 2026, 17:32 | Notification of cessation of securities - AGN | Securities Administration | — | 06027 | |
| 27 July 2026, 09:13 | Investor Presentation - Techknow Conference | Presentations | — | 03026 | |
| 24 July 2026, 09:18 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 16 July 2026, 08:27 | ARG007 Shows Significant Neuroprotection in Concussion Study | Company Update | MS | 11001 | |
| 11 June 2026, 08:33 | Investor Webinar | Presentations | — | 14014 | |
| 11 June 2026, 08:33 | Investor Presentation | Presentations | — | 03026 | |
| 11 June 2026, 08:33 | ARG007 (Xaranetide) Completes All Three FDA Requested Assays | Company Update | MS | 11001 | |
| 10 June 2026, 08:19 | WHO Confirms Xaranetide as INN for ARG-007 | Company Update | MS | 11001 | |
| 9 June 2026, 14:13 | Notification of cessation of securities - AGN | Securities Administration | — | 06027 | |
| 26 May 2026, 09:52 | Release of Securities from Voluntary Escrow | Securities Administration | — | 06009 | |
| 21 May 2026, 09:01 | IND Application Advanced With Successful Completion of Assay | Company Update | MS | 11001 | |
| 14 May 2026, 09:15 | Clinical Advisory Committee Established to Advance Phase 2b | Company Update | MS | 11001 | |
| 29 Apr 2026, 08:20 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 16 Apr 2026, 09:15 | Investor Presentation - Ignite Conference | Presentations | — | 03026 | |
| 26 Mar 2026, 08:13 | Presentations at European Stroke Organisation Conference | Company Administration | MS | 12008 | |
| 17 Mar 2026, 08:19 | Argenica Receives $3.97m R&D Tax Incentive Cash Rebate | Periodic Reports | MS | 03014 | |
| 11 Feb 2026, 08:17 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 5 Feb 2026, 08:23 | Investor Presentation - Euroz Hartleys Healthcare Conference | Presentations | — | 03026 | |
| 2 Feb 2026, 09:01 | Successful Applicaton for EMA Paediatric Waiver | Company Update | MS | 11001 | |
| 28 Jan 2026, 08:15 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 2 Jan 2026, 16:53 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 29 Dec 2025, 08:27 | Non-Executive Chair Resignation | Company Administration | — | 12001, 12017 | |
| 11 Dec 2025, 09:11 | AI Analysis Reveals Efficacy In Severe Stroke Patients | Company Update | MS | 11001 | |
| 4 Dec 2025, 08:17 | Positive TNK Study Results Fulfil Key FDA Requirement | Company Update | MS | 11001 | |
| 25 Nov 2025, 09:16 | ARG-007 Efficacious Dose Validated in New Preclinical Study | Company Update | MS | 11001 | |
| 12 Nov 2025, 19:05 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 12 Nov 2025, 19:03 | Results of Annual General Meeting | Meetings & Governance | — | 08003 | |
| 12 Nov 2025, 16:53 | AGM Chair's Address & Presentation | Presentations | — | 03026, 15002 | |
| 12 Nov 2025, 16:49 | Non-Executive Director Retirement | Company Administration | — | 12001 | |
| 31 Oct 2025, 09:16 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 21 Oct 2025, 09:04 | Investor Presentation - Cannacord Dug & Device Conference | Presentations | — | 03026 | |
| 20 Oct 2025, 13:16 | Notification regarding unquoted securities - AGN | Securities Administration | — | 06021 | |
| 15 Oct 2025, 08:28 | Phase 2 Trial Promising Improvements in Functional Outcomes | Company Update | MS | 11001 | |
| 13 Oct 2025, 14:09 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 24 Sept 2025, 10:49 | ASX Small Caps Conference Presentation | Presentations | — | 03026 | |
| 17 Sept 2025, 08:57 | Date of AGM & Closing Date for Director Nominations | Meetings & Governance | — | 08006, 12008 | |
| 4 Sept 2025, 08:17 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 3 Sept 2025, 09:37 | Investor Webinar | Company Administration | — | 12008 | |
| 3 Sept 2025, 09:35 | Investor Presentation | Presentations | — | 03026 | |
| 3 Sept 2025, 09:34 | Topline Phase 2 Trial Results of ARG-007 in AIS Patients | Company Update | MS | 09014, 11001 | |
| 1 Sept 2025, 09:01 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 28 Aug 2025, 17:06 | Appendix 4G & Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 28 Aug 2025, 17:05 | Appendix 4E & Annual Report to 30 June 2025 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 14 Aug 2025, 09:08 | Argenica Receives IND Feedback From FDA | Company Update | MS | 11001 | |
| 8 Aug 2025, 09:11 | Bioshares Biotech Summit Presentation | Presentations | — | 03026 |
1–50 of 51
1 / 2